Prediction of Duration of Traffic Incidents by Hybrid Deep Learning Based on Multi-Source Incomplete Data. [PDF]
Shang Q, Xie T, Yu Y.
europepmc +1 more source
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source
Constructing a binary prediction model with incomplete data: Variable selection to balance fairness and precision. [PDF]
Ren H, Wang C, Xu G, Weiss DJ.
europepmc +1 more source
Negative COVID-19 excess mortality in the Philippines: outcome of public health measure or product of incomplete data? [PDF]
Del Castillo FA.
europepmc +1 more source
Clustering Incomplete Ordinal Data
Full text is available to authenticated members of The University of Auckland only.The issue of missing data is a common problem for researchers and data analysts working with surveys and other types of questionnaires that use ordinal data.
Sun, Xiaobin
core
Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez +10 more
wiley +1 more source
Handling errors in the response: Considerations for leveraging unsupervised or incomplete data for genetic evaluations. [PDF]
Wu XL +4 more
europepmc +1 more source
Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data. [PDF]
De Salazar PM +16 more
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
G-formula with multiple imputation for causal inference with incomplete data. [PDF]
Bartlett JW +5 more
europepmc +1 more source

